Marinus Pharmaceuticals’ (MRNS) Buy Rating Reaffirmed at HC Wainwright

Marinus Pharmaceuticals (NASDAQ:MRNS)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a report released on Tuesday, Benzinga reports. They presently have a $27.00 target price on the biopharmaceutical company’s stock.

A number of other brokerages have also issued reports on MRNS. Robert W. Baird restated a “neutral” rating on shares of Marinus Pharmaceuticals in a research report on Tuesday. Oppenheimer reissued a “market perform” rating and set a $9.00 price target on shares of Marinus Pharmaceuticals in a research report on Thursday, March 7th. Cantor Fitzgerald restated an “overweight” rating and set a $28.00 price objective on shares of Marinus Pharmaceuticals in a research note on Wednesday, April 10th. Royal Bank of Canada reiterated a “sector perform” rating and set a $3.00 target price (down from $24.00) on shares of Marinus Pharmaceuticals in a research report on Monday. Finally, StockNews.com cut Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, March 6th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $18.21.

Marinus Pharmaceuticals Stock Performance

MRNS opened at $1.44 on Tuesday. The company has a debt-to-equity ratio of 5.68, a current ratio of 4.07 and a quick ratio of 4.01. The business has a fifty day simple moving average of $8.72 and a 200 day simple moving average of $8.45. Marinus Pharmaceuticals has a 1 year low of $1.11 and a 1 year high of $11.26. The company has a market capitalization of $79.10 million, a PE ratio of -0.55 and a beta of 0.91.

Marinus Pharmaceuticals (NASDAQ:MRNS) last announced its earnings results on Tuesday, March 5th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.10). Marinus Pharmaceuticals had a negative net margin of 456.31% and a negative return on equity of 269.75%. The business had revenue of $7.19 million during the quarter, compared to the consensus estimate of $7.78 million. During the same period in the previous year, the firm posted ($0.76) EPS. Research analysts expect that Marinus Pharmaceuticals will post -2.43 EPS for the current year.

Hedge Funds Weigh In On Marinus Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Vanguard Group Inc. grew its position in Marinus Pharmaceuticals by 3.7% in the fourth quarter. Vanguard Group Inc. now owns 2,673,231 shares of the biopharmaceutical company’s stock valued at $29,058,000 after acquiring an additional 95,756 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Marinus Pharmaceuticals by 54.8% in the 4th quarter. Wellington Management Group LLP now owns 241,299 shares of the biopharmaceutical company’s stock valued at $2,623,000 after purchasing an additional 85,455 shares in the last quarter. Barclays PLC boosted its stake in shares of Marinus Pharmaceuticals by 747.4% in the 4th quarter. Barclays PLC now owns 76,372 shares of the biopharmaceutical company’s stock valued at $830,000 after purchasing an additional 67,360 shares in the last quarter. Nuveen Asset Management LLC grew its holdings in shares of Marinus Pharmaceuticals by 1.1% during the 4th quarter. Nuveen Asset Management LLC now owns 139,752 shares of the biopharmaceutical company’s stock valued at $1,519,000 after purchasing an additional 1,475 shares during the last quarter. Finally, Royal Bank of Canada increased its position in Marinus Pharmaceuticals by 124.1% during the 4th quarter. Royal Bank of Canada now owns 15,364 shares of the biopharmaceutical company’s stock worth $167,000 after purchasing an additional 8,507 shares in the last quarter. Institutional investors and hedge funds own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.